These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 27183782)
41. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Zhao J; Zhao Y; Hu Y; Peng J Cell Mol Biol Lett; 2021 Jul; 26(1):32. PubMed ID: 34233623 [TBL] [Abstract][Full Text] [Related]
42. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Chu ZL; Carroll C; Chen R; Alfonso J; Gutierrez V; He H; Lucman A; Xing C; Sebring K; Zhou J; Wagner B; Unett D; Jones RM; Behan DP; Leonard J Mol Endocrinol; 2010 Jan; 24(1):161-70. PubMed ID: 19901198 [TBL] [Abstract][Full Text] [Related]
43. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Li Z; Qiu Q; Geng X; Yang J; Huang W; Qian H Expert Opin Investig Drugs; 2016 Aug; 25(8):871-90. PubMed ID: 27171154 [TBL] [Abstract][Full Text] [Related]
44. Modulating GPR40: therapeutic promise and potential in diabetes. Poitout V; Lin DC Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395 [TBL] [Abstract][Full Text] [Related]
45. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes. Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013 [TBL] [Abstract][Full Text] [Related]
46. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. Ritter K; Buning C; Halland N; Pöverlein C; Schwink L J Med Chem; 2016 Apr; 59(8):3579-92. PubMed ID: 26512410 [TBL] [Abstract][Full Text] [Related]
47. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Nieto A; Fernández-Vega V; Spicer TP; Sturchler E; Adhikari P; Kennedy N; Mandat S; Chase P; Scampavia L; Bannister T; Hodder P; McDonald PH Assay Drug Dev Technol; 2018 Jul; 16(5):278-288. PubMed ID: 30019946 [TBL] [Abstract][Full Text] [Related]
48. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus. Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065 [TBL] [Abstract][Full Text] [Related]
49. Investigational insulin secretagogues for type 2 diabetes. Scheen AJ Expert Opin Investig Drugs; 2016; 25(4):405-22. PubMed ID: 26881467 [TBL] [Abstract][Full Text] [Related]
50. Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review. Nema P; Asati V; Kendya P; Gupta T; Agarwal S; Kori S; Kashaw V; Iyer AK; Kashaw SK Mini Rev Med Chem; 2023; 23(21):2008-2040. PubMed ID: 36861804 [TBL] [Abstract][Full Text] [Related]
51. Rhodiola crenulata root ameliorates derangements of glucose and lipid metabolism in a rat model of the metabolic syndrome and type 2 diabetes. Wang J; Rong X; Li W; Yang Y; Yamahara J; Li Y J Ethnopharmacol; 2012 Aug; 142(3):782-8. PubMed ID: 22683493 [TBL] [Abstract][Full Text] [Related]
52. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice. Al-Barazanji K; McNulty J; Binz J; Generaux C; Benson W; Young A; Chen L J Pharmacol Exp Ther; 2015 Jun; 353(3):496-504. PubMed ID: 25770135 [TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists. Sakairi M; Kogami M; Torii M; Kuno Y; Ohsawa Y; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N Arzneimittelforschung; 2012 Nov; 62(11):537-44. PubMed ID: 22972470 [TBL] [Abstract][Full Text] [Related]
54. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model. Park YH; Choi HH; Lee DH; Chung SY; Yang NY; Kim DH; Ju MK; Han TD; Nam SY; Kim KW Arch Pharm Res; 2017 Jun; 40(6):772-782. PubMed ID: 28593550 [TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure. Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733 [TBL] [Abstract][Full Text] [Related]
56. [Characteristics of the therapy of patients with type II diabetes mellitus and metabolic syndrome]. Bodnar PM; Kononenko LO Lik Sprava; 2000; (7-8):92-4. PubMed ID: 16786661 [TBL] [Abstract][Full Text] [Related]
57. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists. Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471 [TBL] [Abstract][Full Text] [Related]
58. T1R and T2R receptors: the modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus. Dotson CD; Vigues S; Steinle NI; Munger SD Curr Opin Investig Drugs; 2010 Apr; 11(4):447-54. PubMed ID: 20336593 [TBL] [Abstract][Full Text] [Related]
59. Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges. Ghislain J; Poitout V Nat Rev Endocrinol; 2021 Mar; 17(3):162-175. PubMed ID: 33495605 [TBL] [Abstract][Full Text] [Related]